AstraZeneca PLC / Novexel S.A.

Multidrug-Resistant Gram-Negative Bacterial Infections

2.8M US cases/yr

Disease Overview

Multidrug-resistant Gram-negative bacterial infections, including carbapenem-resistant Enterobacteriaceae (CRE), ESBL-producing organisms, and resistant Pseudomonas, are among the most urgent public-health threats. They cause complicated urinary tract and intra-abdominal infections that are difficult to treat because beta-lactamase enzymes destroy most beta-lactam antibiotics, leaving few therapeutic options.

Competitive Landscape

At the time of the December 2009 acquisition, the late-stage Gram-negative antibiotic landscape was thin: Merck's Invanz (ertapenem), Pfizer's Zosyn (piperacillin/tazobactam), and AstraZeneca's own Merrem (meropenem) faced rising resistance, and Forest's Teflaro (ceftaroline) was preparing US filings for skin/CABP. NXL104 (avibactam) was the only late-stage non-beta-lactam beta-lactamase inhibitor active against class A, C, and some class D enzymes, designed to revive ceftazidime and ceftaroline against CRE/ESBL pathogens. The AstraZeneca-Forest co-development structure split US economics on CAZ104 and CEF104 and gave AstraZeneca control of an asset that ultimately became Avycaz (ceftazidime/avibactam, FDA-approved 2015) and underpinned Pfizer's later $15B Hospira-AstraZeneca antibiotic acquisitions. The deal positioned AZ as the most credible Gram-negative antibiotics player at a moment when GSK and Wyeth were retrenching, and it converted a single French biotech asset into a franchise that anchored AZ's small-molecule anti-infective portfolio for a decade.